NeuroSense reports Phase 2b neurology results of PrimeC

NeuroSense announced the presentation of data from the company’s PARADIGM Phase 2b study of PrimeC during an Emerging Science session at the American Academy of Neurology Annual Meeting, which validates the previously announced topline data. The study also demonstrated a positive trend toward impact on Neurofilament levels. The study showed that PrimeC, a formulation of specific doses of ciprofloxacin and celecoxib, met safety and tolerability measures as well as statistically significant slowing of disease progression as demonstrated by the ALSFRS-R by 37% in the per-protocol population. Further, the data showed supporting trends in biomarkers, specifically Neurofilament.